Title |
Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia
|
---|---|
Published in |
ImmunoTargets and Therapy, February 2016
|
DOI | 10.2147/itt.s80648 |
Pubmed ID | |
Authors |
Jose Perdomo |
Abstract |
Romiplostim is a thrombopoietin receptor agonist (TPO-RA) used for the treatment of adult primary immune thrombocytopenia (ITP). ITP is an autoimmune condition characterized by low platelet counts due to increased destruction and reduced platelet production. First-line interventions include corticosteroids, anti-D, and intravenous immunoglobulins, while second-line therapies comprise splenectomy, rituximab, cyclosporine A, and TPO-RAs. The recognition that compromised platelet production is a critical part of the pathogenesis of ITP prompted the development of therapeutic strategies based on the stimulation of the TPO receptor. TPO-RAs enhance megakaryocyte proliferation, increase platelet production, and lead to a reduction in bleeding episodes in ITP patients. This review will summarize current data on the TPO-RA romiplostim, with a particular focus on its relation to splenectomy. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 19 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 3 | 16% |
Student > Master | 3 | 16% |
Other | 2 | 11% |
Researcher | 2 | 11% |
Unspecified | 2 | 11% |
Other | 3 | 16% |
Unknown | 4 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 42% |
Biochemistry, Genetics and Molecular Biology | 4 | 21% |
Unspecified | 2 | 11% |
Unknown | 5 | 26% |